SEC Form 4 · accession 0001209191-19-001525
Odonate Therapeutics, Inc. · ODT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph P O'Connell
Officer — Chief Medical Officer
Period of report
Dec 31, 2018
Accepted (ET)
Jan 3, 2019 · 8:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001717452
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2018 | A | 74 | $11.97 | A | 602 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $14.08 | Dec 31, 2018 | A | 80,074 | A | — | Dec 31, 2028 | Common Stock | 80,074 | 80,074 | D |
Explanation of responses
- F1These shares were acquired on 12/31/2018 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F2The stock options vest with respect to 25% of the underlying shares on 12/31/2019, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.